Racial disparities in immune-related adverse events of immune checkpoint inhibitors and association with survival based on clinical and biochemical responses

Table 1 Patient characteristics

			irAE
	Overall		Yes		No
	n	%	n	%	n	%
Gender							0.8120
Female	129	44.0	41	45.1	88	43.6
Male	164	56.0	50	54.9	114	56.4
Race							0.0141
White	140	47.8	55	60.4	85	42.1
Black	122	41.6	28	30.8	94	46.5
Asian	13	4.4	4	4.4	9	4.5
Hispanic	2	0.7	0	0	2	1.0
Native American	1	0.3	1	1.1	0	0
Other	11	3.8	1	1.1	10	5.0
Unknown	4	1.4	2	2.2	2	1.0
Death							0.1488
No	131	44.7	35	38.5	96	47.5
Yes	162	55.3	56	61.5	106	52.5
PDL1 positive							0.0695
Yes	71	24.2	25	27.5	46	22.8
No	70	23.9	15	16.5	55	27.2
Missing	152	51.9	51	56.0	101	50.0
PDL1 expression							0.0354
< 50%	69	23.5	16	17.6	53	26.2
≥ 50%	32	10.9	14	15.4	18	8.9
Missing	192	65.5	61	67.0	131	64.9
Line of therapy							0.9432
1	85	29.0	29	31.9	56	27.7
2	130	44.4	37	40.7	93	46.0
3	35	11.9	12	13.2	23	11.4
4	17	5.8	5	5.5	12	5.9
5	8	2.7	2	2.2	6	3.0
6	2	0.7	1	1.1	1	0.5
7	2	0.7	0	0	2	1.0
8	1	0.3	0	0	1	0.5
Missing	13	4.4	5	5.5	8	4.0
Progression							0.0140
Yes	121	41.3	28	30.8	93	46.0
No	172	58.7	63	69.2	109	54.0

irAE: Immune-related adverse events; PDL1: Programmed death ligand 1.

Table 2 Patient characteristics

				irAE
	Overall			Yes			No			P value
	n	mean	SD	n	mean	SD	n	mean	SD
Age at ICPi initiation	293	63.3	12.8	91	66.1	13.2	202	62.0	12.4	0.0108

irAE: Immune-related adverse events; ICPi: Immune checkpoint inhibitors.

Table 3 Patient characteristics

				irAE
	Overall			Yes			No			P value
	n	Median	(Q1, Q3)	n	Median	(Q1, Q3)	n	Median	(Q1, Q3)
Number of cycles of immunotherapy	277	5	(2, 12)	82	8.0	(3.0, 19.0)	195	4.0	(2.0, 9.0)	0.0011
LDH	55	243	(171, 290)	25	190	(163, 259)	30	253	(186, 383)	0.0376
Progression free survival (mo)	118	3.9	(1.9, 7.4)	27	5.8	(2.7, 13.0)	91	3.0	(1.7, 6.8)	0.0204
Overall survival (mo)	288	11.5	(2.9, 19.4)	89	17.1	(8.4, 23.5)	199	7.2	(2.1, 15.3)	< 0.0001

irAE: Immune-related adverse events.

Table 4 Progression free survival and overall survival calculated using Wilcoxon rank sum test for comparison

		Overall, n (%)	irAE, n (%)	irAE, Median PFS (mo)	P value	irAE, Median OS (mo)	P value	Endo irAE, n (%)	Endo irAE, Median PFS (mo)	P value	Endo irAE, Median OS (mo)	P value
Gender	Female	129 (44)	41 (45.1)	6.3	0.8977	16.3	0.4756	18 (48.7)	7.7	0.8542	17.0	0.9495
	Male	164 (56)	50 (54.9)	5.7		18.5		19 (51.4)	5.7		17.0
Race	White	140 (47.8)	55 (60.4)	7.7	0.4601	20.6	0.0237	23 (62.2)	10.4	0.2243	21.8	0.0356
	Black	122 (41.6)	28 (30.8)	5.8		12.9		13 (35.1)	5.2		15.8
	Others	31 (10.6)	8(8.8)	2.2		16.0		1 (2.7)			6.2
PDL1 Expression	< 50%	69 (23.5)	16 (17.6)	5.2	0.6985	14.2	0.6468	3 (25.0)	5.2	1.000	16.5	1.0000
	> 50%	32 (10.9)	14 (15.4)	6.3		16.6		9 (75.0)	6.3		15.8

PFS: Progression free survival; OS: Overall survival; irAE: Immune-related adverse events; PDL1: Programmed death ligand 1.